

**Press Release: for immediate release**

## **AQUARIUS SURGICAL TECHNOLOGIES (CSE – ASTI) CLOSES ON \$1.4 MILLION PRIVATE PLACEMENT**

**Halifax, Nova Scotia, July 10, 2017:** Aquarius Surgical Technologies (the “Company”) (CSE – ticker symbol **ASTI**) announces that on July 6, 2017, it closed a private placement of Units to raise \$1,412,430.

The placement consisted of 1,412,430 Class A Units at the price of \$1 per Unit. Each Class “A” Unit comprises One (1) fully paid and non-assessable common share from the Treasury of the Company and One (1) Class A Warrant, exercisable for a period of two years from the date of issue at a price of \$1.50. Each Class A Warrant will entitle the holder to purchase One (1) Class B Unit. Each Class B Unit will comprise One (1) fully paid non-assessable common share from the Treasury of the Company and One (1) Class B Warrant. Each Class B Warrant will entitle the holder to purchase one fully paid common share from the treasury of the Company, at a price of \$2.50, for a period of one year from the date of issue of the Class B Unit. **Callable Warrant Feature:** Class A Warrants and Class B Warrants each have a “Callable” feature, empowering the Company to Call the Warrant for exercise at any time while they are outstanding if the average closing price of the stock on the market over a period of 20 trading days in any period of thirty consecutive trading days is at or above 130% of the respective exercise price of the Warrants. The Call procedure provides that that the Company may give Notice to Exercise within 30 days, after which date any unexercised Warrants will become void. All securities issued in the private placement are subject to a restrictive “hold period” of four months and one day from June 6, 2017, as provided for in applicable securities regulations. Of the funds raised, \$706,215 has been allocated towards implementation of business expansion, and the balance has been allocated to reduce debt on the Balance Sheet.

**About the Company.** Aquarius Surgical Technologies Inc., through its wholly-owned subsidiary Surgical Lasers Inc., is an exclusive provider of innovative, minimally invasive medical laser systems and consumables for multiple medical disciplines, principally in the field of urology. Solutions comprise multiple laser systems, consumables, clinical education, service, support and maintenance and focus on increasing the availability of services for patients, enhancing the quality of patient care, improving operational efficiencies and reducing total operational costs.

The Company’s flagship portable BPH laser remains the only device in its class boasting the highest output energy of any portable device and supporting all available fiber delivery systems (contact and lateral-fire for photo-selective vaporization of the prostate and end-fire for enucleation). Based on its portability, performance and its proven clinical efficacy and safety it remain the only office-based alternative, facilitating safe, efficient and effective BPH surgery in a clear operative field under both local and general anaesthetic alternatives.

The first shipment of the new Uni-core fiber (the consumable for the portable BPH laser) which offers greater performance and durability has been successfully implemented in reference sites across the US. All future production of this fiber will incorporate the Uni-core design.

The recent FDA approval and launch of the Company’s new compact holmium laser for lithotripsy, including treatment of upper ureter kidney stones, represents an evolution in the laser lithotripsy industry, as it is the only portable laser in the world with ability to alter the pulse widths to support long fragmentation as well as the ability to deliver 30 watts of energy down the 200 micron fiber. Long fragmentation significantly reduces treatment time as it fragments the stones into pieces so small, it eliminates the requirement for basket retrieval which is typically required with other systems. The ability to deliver higher energy down smaller diameter fibers, which are often required for access especially in the upper ureter, means performance is not compromised for access.

*Neither Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release.*

For further information, please contact:  
Lorne S MacFarlane  
Chief Financial Officer  
(902) 496-7594  
[email: lornemac@eastlink.ca](mailto:lorne@eastlink.ca)